The company has issued tens of thousands of corrected reports to patients and doctors after reportedly taking its Edison blood testing machines out of service last June.READ MORE: COVID Reopening: Burning Man Mulling Proof Of Vaccination For August 2021 Festival
The Wall Street Journal reports the move raises the possibility that many health care decisions may have been made based on inaccurate data.
Theranos’ Edison machine was seen as a key innovation leading to the company’s $9 billion valuation.READ MORE: San Francisco Considers Spending Hundreds of Millions on Safe Sleeping Sites For Homeless
The machine was designed to perform a range of diagnostic tests from a single drop of blood.
But problems led the company to stop using the machines last June.MORE NEWS: DA Chesa Boudin Touts Police Reform Legislation AB127; SFPOA Pushes Back